The two-year IWT-funded project aims to advance compounds against human rhinovirus (HRV), the virus that causes the common cold and hepatitis C virus (HCV), with the target to bring out a first preclinical candidate within the next one year.
Galapagos will collaborate on this project with the research group of professor Johan Neyts at the Rega Institute for Medical Research at the KU Leuven.
Galapagos SVP of Drug Discovery Graham Dixon said the grant provides funding for them to further understand the mechanism by which these orally available, small molecules play a role in inhibiting viral infection.